TB Medicine Pretomanid Enters Regulatory Review Process in the United States

NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news